Share Price and Basic Stock Data
Last Updated: October 26, 2025, 10:25 am
| PEG Ratio | -9.87 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Aashka Hospitals Ltd operates in the Hospitals & Medical Services sector, with its share price recorded at ₹78.40 and a market capitalization of ₹183 Cr. The company’s revenue trends have shown volatility over recent quarters. Sales peaked at ₹28.42 Cr in September 2021 but have since experienced a decline, with the latest reported sales of ₹10.80 Cr in September 2023 and ₹12.07 Cr in March 2024. The annual sales figures illustrate a similar trend, with a high of ₹40.69 Cr in March 2021, which dwindled to ₹18.94 Cr by March 2023. The operating profit margin (OPM) has also suffered, declining to -2.04% in March 2025 from a high of 31.70% in September 2021. This decline in revenue and profitability metrics raises concerns about the company’s operational efficiency and market competitiveness.
Profitability and Efficiency Metrics
The profitability metrics for Aashka Hospitals Ltd reflect a challenging operational environment. The reported net profit stood at ₹3.27 Cr for FY 2025, indicating a recovery from prior losses of ₹2.10 Cr in March 2023. However, the return on equity (ROE) is low at 2.39%, and the return on capital employed (ROCE) is even lower at 4.07%, signaling inefficiencies in utilizing capital for generating profits. The interest coverage ratio (ICR) is relatively strong at 4.41x, suggesting the company can cover its interest expenses comfortably. Despite this, the company’s cash conversion cycle (CCC) of 4.23 days indicates a return to more efficient working capital management following a troubling increase to 132.20 days in March 2023. Overall, while the net profit is a positive sign, the low ROE and ROCE raise concerns about long-term profitability and operational efficiency.
Balance Sheet Strength and Financial Ratios
Aashka Hospitals Ltd’s balance sheet shows a mixed picture of financial health. Total borrowings have decreased significantly to ₹12.61 Cr from ₹29.19 Cr in March 2023, indicating a positive trend in reducing debt levels. The company’s reserves stood at ₹76.17 Cr, providing a cushion against future uncertainties. The debt-to-equity ratio is low at 0.12, suggesting a conservative capital structure which typically favors long-term stability. However, the price-to-book value ratio (P/BV) of 2.40x may indicate that the stock is overvalued compared to its book value, which stood at ₹42.60 per share. Current and quick ratios are reported at 1.29x and 1.25x respectively, reflecting adequate liquidity to meet short-term obligations. While the balance sheet is not excessively leveraged, the high P/BV and low profitability ratios could deter potential investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aashka Hospitals Ltd reveals a stable ownership structure, with promoters holding 61.28% of the equity since September 2021, indicating strong management control. The public stake is reported at 38.72%, with a declining number of shareholders, which decreased from 2,771 in September 2021 to 1,174 by March 2025. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may point to a lack of broader institutional confidence in the company. The declining shareholder count could suggest diminishing interest from retail investors, which might impact liquidity in the stock. This stable yet shrinking base of retail investors could pose risks to future capital raising efforts and market perception.
Outlook, Risks, and Final Insight
If Aashka Hospitals Ltd can sustain its recent recovery in net profit and continue to manage its expenses effectively, it may improve its profitability metrics over the coming quarters. However, significant risks remain, including the potential for ongoing revenue volatility and low return ratios, which could affect investor sentiment. Additionally, the high P/BV ratio raises concerns about valuation, especially in a sector where competition is intensifying. Should the company succeed in enhancing operational efficiency and stabilizing revenue streams, it could attract institutional interest, thereby improving its market position. Conversely, failure to address these operational challenges may hinder growth and investor confidence, leading to continued stock underperformance. Overall, while there are signs of recovery, the company must navigate its operational hurdles to realize its potential in the sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Aashka Hospitals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 49.3 Cr. | 147 | 195/140 | 6.63 | 115 | 2.38 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.6 Cr. | 22.5 | 37.6/0.00 | 25.5 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 13.0 Cr. | 12.6 | 23.4/12.0 | 145 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 129 Cr. | 68.6 | 98.7/51.3 | 27.9 | 16.1 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 23.9 Cr. | 4.42 | 7.73/3.40 | 0.81 | 2.49 | 0.00 % | 79.2 % | 85.5 % | 10.0 |
| Industry Average | 29,122.21 Cr | 853.95 | 67.31 | 94.89 | 0.31% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 24.82 | 28.42 | 11.32 | 11.54 | 7.41 | 10.80 | 12.07 | 12.36 | 10.28 |
| Expenses | 19.41 | 19.41 | 12.06 | 10.80 | 7.91 | 9.97 | 8.44 | 7.89 | 10.49 |
| Operating Profit | 5.41 | 9.01 | -0.74 | 0.74 | -0.50 | 0.83 | 3.63 | 4.47 | -0.21 |
| OPM % | 21.80% | 31.70% | -6.54% | 6.41% | -6.75% | 7.69% | 30.07% | 36.17% | -2.04% |
| Other Income | 0.04 | 0.04 | 0.09 | 0.06 | 3.06 | 2.61 | 1.61 | 0.07 | 4.20 |
| Interest | 1.43 | 1.43 | 1.23 | -0.17 | 3.17 | 1.46 | 1.45 | 1.02 | 0.70 |
| Depreciation | 1.45 | 1.45 | 1.44 | 1.44 | 1.49 | 1.47 | 1.45 | 1.58 | 1.37 |
| Profit before tax | 2.57 | 6.17 | -3.32 | -0.47 | -2.10 | 0.51 | 2.34 | 1.94 | 1.92 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 17.65% | 17.09% | 16.49% | 14.58% |
| Net Profit | 2.57 | 6.17 | -3.33 | -0.47 | -2.10 | 0.42 | 1.93 | 1.62 | 1.65 |
| EPS in Rs | 1.43 | 2.64 | -1.42 | -0.20 | -0.90 | 0.18 | 0.82 | 0.69 | 0.71 |
Last Updated: May 31, 2025, 7:13 am
Below is a detailed analysis of the quarterly data for Aashka Hospitals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 10.28 Cr.. The value appears to be declining and may need further review. It has decreased from 12.36 Cr. (Sep 2024) to 10.28 Cr., marking a decrease of 2.08 Cr..
- For Expenses, as of Mar 2025, the value is 10.49 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.89 Cr. (Sep 2024) to 10.49 Cr., marking an increase of 2.60 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.21 Cr.. The value appears to be declining and may need further review. It has decreased from 4.47 Cr. (Sep 2024) to -0.21 Cr., marking a decrease of 4.68 Cr..
- For OPM %, as of Mar 2025, the value is -2.04%. The value appears to be declining and may need further review. It has decreased from 36.17% (Sep 2024) to -2.04%, marking a decrease of 38.21%.
- For Other Income, as of Mar 2025, the value is 4.20 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Sep 2024) to 4.20 Cr., marking an increase of 4.13 Cr..
- For Interest, as of Mar 2025, the value is 0.70 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.02 Cr. (Sep 2024) to 0.70 Cr., marking a decrease of 0.32 Cr..
- For Depreciation, as of Mar 2025, the value is 1.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.58 Cr. (Sep 2024) to 1.37 Cr., marking a decrease of 0.21 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.92 Cr.. The value appears to be declining and may need further review. It has decreased from 1.94 Cr. (Sep 2024) to 1.92 Cr., marking a decrease of 0.02 Cr..
- For Tax %, as of Mar 2025, the value is 14.58%. The value appears to be improving (decreasing) as expected. It has decreased from 16.49% (Sep 2024) to 14.58%, marking a decrease of 1.91%.
- For Net Profit, as of Mar 2025, the value is 1.65 Cr.. The value appears strong and on an upward trend. It has increased from 1.62 Cr. (Sep 2024) to 1.65 Cr., marking an increase of 0.03 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.71. The value appears strong and on an upward trend. It has increased from 0.69 (Sep 2024) to 0.71, marking an increase of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:05 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 27.67 | 27.23 | 40.69 | 39.73 | 18.94 | 22.87 | 22.65 |
| Expenses | 18.08 | 18.41 | 30.72 | 31.16 | 18.59 | 18.41 | 18.37 |
| Operating Profit | 9.59 | 8.82 | 9.97 | 8.57 | 0.35 | 4.46 | 4.28 |
| OPM % | 34.66% | 32.39% | 24.50% | 21.57% | 1.85% | 19.50% | 18.90% |
| Other Income | 0.06 | 0.02 | 0.00 | 0.13 | 3.10 | 4.21 | 4.26 |
| Interest | 5.75 | 4.90 | 3.25 | 2.96 | 3.09 | 2.91 | 1.72 |
| Depreciation | 2.54 | 2.56 | 2.61 | 2.90 | 2.93 | 2.92 | 2.95 |
| Profit before tax | 1.36 | 1.38 | 4.11 | 2.84 | -2.57 | 2.84 | 3.87 |
| Tax % | 0.00% | 0.00% | 0.00% | 16.55% | 0.00% | 17.25% | 15.50% |
| Net Profit | 1.36 | 1.38 | 4.11 | 2.37 | -2.57 | 2.36 | 3.27 |
| EPS in Rs | 0.76 | 0.77 | 2.28 | 1.01 | -1.10 | 1.01 | 1.40 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 1.47% | 197.83% | -42.34% | -208.44% | 191.83% | 38.56% |
| Change in YoY Net Profit Growth (%) | 0.00% | 196.36% | -240.16% | -166.10% | 400.27% | -153.27% |
Aashka Hospitals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -4% |
| 3 Years: | -17% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 0% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 1% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: September 10, 2025, 2:52 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 17.16 | 17.91 | 18.00 | 23.37 | 23.37 | 23.37 | 23.37 |
| Reserves | -1.80 | 6.28 | 11.25 | 73.20 | 70.55 | 72.91 | 76.17 |
| Borrowings | 32.99 | 30.92 | 27.87 | 28.21 | 29.19 | 20.39 | 12.61 |
| Other Liabilities | 5.71 | 4.93 | 7.96 | 4.34 | 4.92 | 4.78 | 3.91 |
| Total Liabilities | 54.06 | 60.04 | 65.08 | 129.12 | 128.03 | 121.45 | 116.06 |
| Fixed Assets | 46.36 | 44.12 | 49.49 | 48.46 | 45.47 | 42.78 | 40.79 |
| CWIP | 0.08 | 0.00 | 0.00 | 0.00 | 0.05 | 0.45 | 0.88 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 7.62 | 15.92 | 15.59 | 80.66 | 82.51 | 78.22 | 74.39 |
| Total Assets | 54.06 | 60.04 | 65.08 | 129.12 | 128.03 | 121.45 | 116.06 |
Below is a detailed analysis of the balance sheet data for Aashka Hospitals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 23.37 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 23.37 Cr..
- For Reserves, as of Mar 2025, the value is 76.17 Cr.. The value appears strong and on an upward trend. It has increased from 72.91 Cr. (Mar 2024) to 76.17 Cr., marking an increase of 3.26 Cr..
- For Borrowings, as of Mar 2025, the value is 12.61 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 20.39 Cr. (Mar 2024) to 12.61 Cr., marking a decrease of 7.78 Cr..
- For Other Liabilities, as of Mar 2025, the value is 3.91 Cr.. The value appears to be improving (decreasing). It has decreased from 4.78 Cr. (Mar 2024) to 3.91 Cr., marking a decrease of 0.87 Cr..
- For Total Liabilities, as of Mar 2025, the value is 116.06 Cr.. The value appears to be improving (decreasing). It has decreased from 121.45 Cr. (Mar 2024) to 116.06 Cr., marking a decrease of 5.39 Cr..
- For Fixed Assets, as of Mar 2025, the value is 40.79 Cr.. The value appears to be declining and may need further review. It has decreased from 42.78 Cr. (Mar 2024) to 40.79 Cr., marking a decrease of 1.99 Cr..
- For CWIP, as of Mar 2025, the value is 0.88 Cr.. The value appears strong and on an upward trend. It has increased from 0.45 Cr. (Mar 2024) to 0.88 Cr., marking an increase of 0.43 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 74.39 Cr.. The value appears to be declining and may need further review. It has decreased from 78.22 Cr. (Mar 2024) to 74.39 Cr., marking a decrease of 3.83 Cr..
- For Total Assets, as of Mar 2025, the value is 116.06 Cr.. The value appears to be declining and may need further review. It has decreased from 121.45 Cr. (Mar 2024) to 116.06 Cr., marking a decrease of 5.39 Cr..
Notably, the Reserves (76.17 Cr.) exceed the Borrowings (12.61 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -23.40 | -22.10 | -17.90 | -19.64 | -28.84 | -15.93 | -8.33 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 45.64 | 90.48 | 65.66 | 71.84 | 132.20 | 76.93 | 76.06 |
| Inventory Days | 51.35 | 66.55 | 30.28 | 34.97 | 56.59 | 48.75 | 58.63 |
| Days Payable | 296.91 | 247.49 | 241.09 | 101.11 | 365.00 | 263.54 | 130.46 |
| Cash Conversion Cycle | -199.92 | -90.46 | -145.15 | 5.71 | -176.21 | -137.86 | 4.23 |
| Working Capital Days | -93.26 | 19.57 | -38.48 | -34.27 | -126.42 | -123.21 | 3.38 |
| ROCE % | 12.14% | 13.12% | 6.38% | 0.42% | 4.80% | 4.07% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.40 | 1.01 | -1.10 | 1.12 | 2.29 |
| Diluted EPS (Rs.) | 1.40 | 1.01 | -1.10 | 1.12 | 2.29 |
| Cash EPS (Rs.) | 2.66 | 2.26 | 0.15 | 2.25 | 3.73 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 42.60 | 41.20 | 40.19 | 41.32 | 16.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 42.60 | 41.20 | 40.19 | 41.32 | 16.25 |
| Revenue From Operations / Share (Rs.) | 9.69 | 9.79 | 8.11 | 17.00 | 22.60 |
| PBDIT / Share (Rs.) | 3.26 | 3.71 | 1.44 | 3.59 | 5.51 |
| PBIT / Share (Rs.) | 2.00 | 2.46 | 0.18 | 2.35 | 4.06 |
| PBT / Share (Rs.) | 1.66 | 1.22 | -1.10 | 1.21 | 2.29 |
| Net Profit / Share (Rs.) | 1.40 | 1.01 | -1.10 | 1.01 | 2.29 |
| PBDIT Margin (%) | 33.62 | 37.92 | 17.75 | 21.12 | 24.36 |
| PBIT Margin (%) | 20.61 | 25.17 | 2.27 | 13.82 | 17.96 |
| PBT Margin (%) | 17.08 | 12.44 | -13.56 | 7.14 | 10.11 |
| Net Profit Margin (%) | 14.42 | 10.30 | -13.56 | 5.95 | 10.11 |
| Return on Networth / Equity (%) | 3.28 | 2.44 | -2.73 | 2.44 | 14.06 |
| Return on Capital Employeed (%) | 4.39 | 5.47 | 0.38 | 4.81 | 14.60 |
| Return On Assets (%) | 2.81 | 1.94 | -2.00 | 1.83 | 6.32 |
| Long Term Debt / Equity (X) | 0.06 | 0.08 | 0.16 | 0.17 | 0.68 |
| Total Debt / Equity (X) | 0.12 | 0.21 | 0.31 | 0.29 | 0.74 |
| Asset Turnover Ratio (%) | 0.19 | 0.18 | 0.14 | 0.40 | 0.65 |
| Current Ratio (X) | 1.29 | 0.64 | 0.79 | 0.82 | 1.01 |
| Quick Ratio (X) | 1.25 | 0.62 | 0.77 | 0.78 | 0.97 |
| Inventory Turnover Ratio (X) | 58.72 | 0.00 | 0.00 | 10.54 | 10.90 |
| Interest Coverage Ratio (X) | 4.41 | 2.98 | 1.12 | 3.16 | 3.10 |
| Interest Coverage Ratio (Post Tax) (X) | 2.36 | 1.81 | 0.14 | 1.89 | 2.29 |
| Enterprise Value (Cr.) | 248.61 | 199.58 | 124.69 | 144.22 | 0.00 |
| EV / Net Operating Revenue (X) | 10.98 | 8.73 | 6.58 | 3.63 | 0.00 |
| EV / EBITDA (X) | 32.65 | 23.00 | 37.06 | 17.18 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 10.54 | 7.92 | 5.20 | 2.95 | 0.00 |
| Price / BV (X) | 2.40 | 1.88 | 1.05 | 1.21 | 0.00 |
| Price / Net Operating Revenue (X) | 10.54 | 7.92 | 5.20 | 2.95 | 0.00 |
| EarningsYield | 0.01 | 0.01 | -0.02 | 0.02 | 0.00 |
After reviewing the key financial ratios for Aashka Hospitals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 1.40. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 23) to 1.40, marking an increase of 0.39.
- For Diluted EPS (Rs.), as of Mar 24, the value is 1.40. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 23) to 1.40, marking an increase of 0.39.
- For Cash EPS (Rs.), as of Mar 24, the value is 2.66. This value is below the healthy minimum of 3. It has increased from 2.26 (Mar 23) to 2.66, marking an increase of 0.40.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 42.60. It has increased from 41.20 (Mar 23) to 42.60, marking an increase of 1.40.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 42.60. It has increased from 41.20 (Mar 23) to 42.60, marking an increase of 1.40.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 9.69. It has decreased from 9.79 (Mar 23) to 9.69, marking a decrease of 0.10.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 3.26. This value is within the healthy range. It has decreased from 3.71 (Mar 23) to 3.26, marking a decrease of 0.45.
- For PBIT / Share (Rs.), as of Mar 24, the value is 2.00. This value is within the healthy range. It has decreased from 2.46 (Mar 23) to 2.00, marking a decrease of 0.46.
- For PBT / Share (Rs.), as of Mar 24, the value is 1.66. This value is within the healthy range. It has increased from 1.22 (Mar 23) to 1.66, marking an increase of 0.44.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 1.40. This value is below the healthy minimum of 2. It has increased from 1.01 (Mar 23) to 1.40, marking an increase of 0.39.
- For PBDIT Margin (%), as of Mar 24, the value is 33.62. This value is within the healthy range. It has decreased from 37.92 (Mar 23) to 33.62, marking a decrease of 4.30.
- For PBIT Margin (%), as of Mar 24, the value is 20.61. This value exceeds the healthy maximum of 20. It has decreased from 25.17 (Mar 23) to 20.61, marking a decrease of 4.56.
- For PBT Margin (%), as of Mar 24, the value is 17.08. This value is within the healthy range. It has increased from 12.44 (Mar 23) to 17.08, marking an increase of 4.64.
- For Net Profit Margin (%), as of Mar 24, the value is 14.42. This value exceeds the healthy maximum of 10. It has increased from 10.30 (Mar 23) to 14.42, marking an increase of 4.12.
- For Return on Networth / Equity (%), as of Mar 24, the value is 3.28. This value is below the healthy minimum of 15. It has increased from 2.44 (Mar 23) to 3.28, marking an increase of 0.84.
- For Return on Capital Employeed (%), as of Mar 24, the value is 4.39. This value is below the healthy minimum of 10. It has decreased from 5.47 (Mar 23) to 4.39, marking a decrease of 1.08.
- For Return On Assets (%), as of Mar 24, the value is 2.81. This value is below the healthy minimum of 5. It has increased from 1.94 (Mar 23) to 2.81, marking an increase of 0.87.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.08 (Mar 23) to 0.06, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.12. This value is within the healthy range. It has decreased from 0.21 (Mar 23) to 0.12, marking a decrease of 0.09.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.19. It has increased from 0.18 (Mar 23) to 0.19, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 24, the value is 1.29. This value is below the healthy minimum of 1.5. It has increased from 0.64 (Mar 23) to 1.29, marking an increase of 0.65.
- For Quick Ratio (X), as of Mar 24, the value is 1.25. This value is within the healthy range. It has increased from 0.62 (Mar 23) to 1.25, marking an increase of 0.63.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 58.72. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 23) to 58.72, marking an increase of 58.72.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 4.41. This value is within the healthy range. It has increased from 2.98 (Mar 23) to 4.41, marking an increase of 1.43.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.36. This value is below the healthy minimum of 3. It has increased from 1.81 (Mar 23) to 2.36, marking an increase of 0.55.
- For Enterprise Value (Cr.), as of Mar 24, the value is 248.61. It has increased from 199.58 (Mar 23) to 248.61, marking an increase of 49.03.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 10.98. This value exceeds the healthy maximum of 3. It has increased from 8.73 (Mar 23) to 10.98, marking an increase of 2.25.
- For EV / EBITDA (X), as of Mar 24, the value is 32.65. This value exceeds the healthy maximum of 15. It has increased from 23.00 (Mar 23) to 32.65, marking an increase of 9.65.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 10.54. This value exceeds the healthy maximum of 3. It has increased from 7.92 (Mar 23) to 10.54, marking an increase of 2.62.
- For Price / BV (X), as of Mar 24, the value is 2.40. This value is within the healthy range. It has increased from 1.88 (Mar 23) to 2.40, marking an increase of 0.52.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 10.54. This value exceeds the healthy maximum of 3. It has increased from 7.92 (Mar 23) to 10.54, marking an increase of 2.62.
- For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aashka Hospitals Ltd:
- Net Profit Margin: 14.42%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.39% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.28% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.36
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.25
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 91.7 (Industry average Stock P/E: 67.31)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.12
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.42%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Between Sargasan & Reliance Cross Road, Sargasan, Gandhinagar Gujarat 382421 | cs@aashkahospitals.in http://www.aashkahospitals.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bipinchandra D Shah | Chairman & Managing Director |
| Mrs. Shreyarthi B Shah | Director |
| Mr. Umang A Shah | Independent Director |
| Mr. Jigar K Trivedi | Independent Director |
FAQ
What is the intrinsic value of Aashka Hospitals Ltd?
Aashka Hospitals Ltd's intrinsic value (as of 26 October 2025) is 76.01 which is 17.11% lower the current market price of 91.70, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 215 Cr. market cap, FY2025-2026 high/low of 121/65.1, reserves of ₹76.17 Cr, and liabilities of 116.06 Cr.
What is the Market Cap of Aashka Hospitals Ltd?
The Market Cap of Aashka Hospitals Ltd is 215 Cr..
What is the current Stock Price of Aashka Hospitals Ltd as on 26 October 2025?
The current stock price of Aashka Hospitals Ltd as on 26 October 2025 is 91.7.
What is the High / Low of Aashka Hospitals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aashka Hospitals Ltd stocks is 121/65.1.
What is the Stock P/E of Aashka Hospitals Ltd?
The Stock P/E of Aashka Hospitals Ltd is 91.7.
What is the Book Value of Aashka Hospitals Ltd?
The Book Value of Aashka Hospitals Ltd is 42.5.
What is the Dividend Yield of Aashka Hospitals Ltd?
The Dividend Yield of Aashka Hospitals Ltd is 0.00 %.
What is the ROCE of Aashka Hospitals Ltd?
The ROCE of Aashka Hospitals Ltd is 4.07 %.
What is the ROE of Aashka Hospitals Ltd?
The ROE of Aashka Hospitals Ltd is 2.39 %.
What is the Face Value of Aashka Hospitals Ltd?
The Face Value of Aashka Hospitals Ltd is 10.0.